Incorporating ALL Biology into Treatment Decisions: Next Steps toward Targeted Therapy in Adult ALL

Key Points

• The aim is to enhance treatment decisions in adult acute lymphoblastic leukemia (ALL) by incorporating molecular biology.
• Reviewed recent literature on targeted therapies for ALL.
• Identified high-risk molecular subtypes and their vulnerabilities.
• Evaluated advances in BH3 mimetics, menin inhibitors, and immunotherapy.
• Discussed challenges like treatment resistance and phenotypic escape.
• Defined high-risk molecular subtypes associated with poor outcomes.
• Highlighted effective targeted strategies such as BH3 mimetics and menin inhibitors.
• Addressed critical challenges affecting treatment efficacy and patient responses.